Genprex, Inc. · NASDAQ:GNPX

Genprex — Investor Presentation (January 2022)

49 slides from Genprex's investor presentation, January 2022

  1. Slide 1: Reprogramming the Course of Cancer and Diabetes

    REPROGRAMMING THE COURSE OF CANCER AND DIABETES NASDAQ: GNPX January 2022 Nasdaq: GNPX 1

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual res

  3. Slide 3: GNPX at a Glance

    GNPX AT A GLANCE 10-DAY AVG SHARES COMPANY SYMBOL EXCHANGE SHARE PRICE MARKET CAP CASH VOLUME OUTSTANDING Genprex, Inc. GNPX Nasdaq $1.30 $62M 399K 47,808,570 $42 Million All data are as of December 21, 2021, except for shares outstanding which is as of November 8, 2021, and cash which is as of Sept

  4. Slide 4: Executive Summary

    EXECUTIVE SUMMARY MAJOR COMPETITIVE ADVANTAGES • GENE THERAPY PLATFORM • DEMONSTRATED CLINICAL ACHIEVEMENT • FIRST SYSTEMIC GENE THERAPY • INITIATED ONE LUNG CANCER CLINICAL USED FOR CANCER IN HUMANS TRIAL, EXPECT TO INITIATE SECOND CLINICAL TRIAL IN Q1 2022 • LARGE MARKETS AND UNMET NEED • WORLD-CL

  5. Slide 5: Research and Development Pipeline

    RESEARCH AND DEVELOPMENT PIPELINE Nasdaq: GNPX 5

  6. Slide 6: Bridging Gaps in Modern Medicine

    BRIDGING GAPS IN MODERN MEDICINE HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS ONCOLOGY DIABETES ● REQORSA is the first systemic gene therapy in ● Gene therapy drug candidate addresses Type 1 and development for cancer. Type 2 diabetes. ● Planned clinical trials include combinations of ● May reduc

  7. Slide 7: Oncology Program

    ONCOLOGY PROGRAM Nasdaq: GNPX 7

  8. Slide 8: Non-Small Cell Lung Cancer Market Statistics

    NON-SMALL CELL LUNG CANCER MARKET STATISTICS 84% MOST COMMON LUNG CANCER NSCLC represents the majority of all lung cancers. $4B+ TAGRISSO 2020 SALES AstraZeneca’s highest grossing product. 2M WORLDWIDE CASES More than two million cases per year worldwide. $14B+ KEYTRUDA 2020 SALES Merck’s highest gr

  9. Slide 9: Novel Platform to Treat Cancer

    NOVEL PLATFORM TO TREAT CANCER ONCOPREX® NANOPARTICLE DELIVERY SYSTEM The first systemic gene therapy delivery platform for cancer GENES SYNERGIES Multiple tumor Advanced approach suppressor genes using combination therapy CANCERS Multiple cancers Nasdaq: GNPX 9

  10. Slide 10: Oncoprex Nanoparticle Delivery System

    ONCOPREX NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS Our non-viral, biodegradable, positively-charged lipid nanoparticle (LNP) is delivered systemically and has affinity to negatively-charged cancer cells, with up to a 33-fold uptake in cancer cells vs. normal cel

  11. Slide 11: Targeting Negative Surface Charges of Cancer Cells

    TARGETING NEGATIVE SURFACE CHARGES OF CANCER CELLS AN INNOVATIVE MEANS TO SELECTIVELY TARGET CANCER CELLS • The activities of glucose metabolism have a profound impact on the surface of cancer cells • Elevated glycolysis in cancer cells lead to a higher secretion of lactate • Secreted lactate ions r

  12. Slide 12: REQORSA Targets Cancer at Its Core

    REQORSA™ TARGETS CANCER AT ITS CORE DOTAP: CL-TUSC2 CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer Nasdaq: GNPX 12

  13. Slide 13: TUSC2 Inhibits Key Cell Signaling

    TUSC2 INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS Nasdaq: GNPX 13

  14. Slide 14: REQORSA Monotherapy

    REQORSA MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase 1 monotherapy results: ● 31 Stage IV patients with at least 1 of 6 trial doses ● 23 patients evaluable ● Cancer growth halted in 5 of 23 patients ● Stable disease n=5; responses n=3 ● Highest

  15. Slide 15: REQORSA + Tarceva Combination

    REQORSA + TARCEVA COMBINATION PHASE 2 PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS PRIOR LINES OF PATIENT EGFR STATUS RESPONSE PRIOR THERAPY THERAPY Positive (exon 18+20) Complete Response Chemo 3 Negative 24% regression Target Lesion Chemo / anti-PD1 2 30% regression one Target Lesio

  16. Slide 16: REQORSA + Tarceva Combination

    REQORSA + TARCEVA COMBINATION Nasdaq: GNPX 16

  17. Slide 17: AACR 21: REQORSA + Tagrisso Reduce Tumor Growth in Resistant Tumors

    AACR 21: REQORSA + TAGRISSO REDUCE TUMOR GROWTH IN TAGRISSO-RESISTANT TUMORS Osimertinib is the generic name for Tagrisso. REQORSA referred to as TUSC2 in figures. Nasdaq: GNPX 17

  18. Slide 18: Phase 2 General Study Characteristics: REQORSA + Tagrisso

    GENERAL STUDY CHARACTERISTICS ● REQORSA in combination with AstraZeneca’s Tagrisso for NSCLC • Interim analysis at 25 events (i.e., disease progression or ● FDA Fast Track Designation death) ● Patients with advanced, EGFR mutant NSCLC whose disease progressed after Tagrisso PASE 1 ● ~15 U.S. sites ●

  19. Slide 19: Study Components and Endpoints

    COMPONENT PRIMARY ENDPOINT PHASE 1 ● 3+3 dose escalation of ● Dose limiting toxicity REQORSA in combination with Tagrisso* PRIMARY ENDPOINT SECONDARY ENDPOINTS COMPONENT Randomized 1:1, open-label, ● Progression free survival (PFS) ● Overall response rate PHASE 2 ● 2-arm study of REQORSA in ● PFS im

  20. Slide 20: REQORSA Shows Synergy with Immunotherapies

    REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER TUSC2+anti-PD1 combination significantly prolonged TUSC2+anti-PD1 exhibit greater antitumor activity than survival in a lung metastasis model refractory to either agent alone or

  21. Slide 21: REQORSA Modulates the Immune System

    REQORSA MODULATES THE IMMUNE SYSTEM REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER REQORSA + Keytruda Strong antitumor immune responses of anti-PD1 were found against PDX tumors developed in humanized mice. Immunomodulation of Pembro + TUSC2 demonstrates rationale for

  22. Slide 22: AACR 21: REQORSA May Enhance First-Line Standard of Care

    AACR 21: REQORSA MAY ENHANCE FIRST-LINE STANDARD OF CARE REQORSA MAY OVERCOME RESISTANCE TO KEYTRUDA + CHEMO COMBINATION REQORSA + Keytruda + Chemo • REQORSA enhances the efficacy of chemo-immunotherapy on KL-mutant lung metastases in humanized mice. • Triple combination demonstrated strong antitumo

  23. Slide 23: REQORSA Shows Synergy with Immunotherapy + Chemotherapy

    REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPY + CHEMOTHERAPY A B C REQORSA + Keytruda + Chemo REQORSA+anti-PD1+chemo combination resulted in metastasis regression significantly greater than either REQORSA alone or anti-PD1+chemo. D E Note: Treg and Myeloid cells are immunosuppressive Image: Immunoprofili

  24. Slide 24: Phase 2 General Study Characteristics: REQORSA + Keytruda

    GENERAL STUDY CHARACTERISTICS ● REQORSA in combination with Merck & Co’s Keytruda for NSCLC • Interim analysis at 50 events (i.e., disease progression ● FDA Fast Track Designation (received December 2021) or death) ● Patients with advanced NSCLC whose disease progressed after treatment with • Phase

  25. Slide 25: Study Components and Endpoints

    COMPONENT PRIMARY ENDPOINT PHASE 1 ● 3+3 dose escalation of ● Dose limiting toxicity REQORSA in combination with Keytruda PRIMARY ENDPOINT SECONDARY ENDPOINTS COMPONENT Randomized 2:1, open-label, ● Progression free survival (PFS) ● Overall response rate PHASE 2 ● 2-arm study of REQORSA in ● PFS imp

  26. Slide 26: Scaled-Up Clinical Grade Manufacturing

    SCALED-UP CLINICAL GRADE MANUFACTURING MILESTONE POSITIONS COMPANY FOR SUCCESS IN LUNG CANCER THERAPEUTICS MARKET Achievement highlighted by important process improvements and significantly improved economies of scale. • Successful completion of technology transfer and scale-up of REQORSA • GMP prod

  27. Slide 27: REQORSA in Small Cell Lung Cancer

    REQORSA IN SMALL CELL LUNG CANCER EXPANDING REQORSA FOR THE ENTIRE LUNG CANCER MARKET Targeting Small Cell Lung Cancer (in addition to NSCLC) allows Genprex to address the entire lung cancer market. Small Cell Lung Cancer: • Consistently has low TUSC2 protein levels • Documented to often have deleti

  28. Slide 28: Diabetes Program

    DIABETES PROGRAM Nasdaq: GNPX 28

  29. Slide 29: Diabetic Patients in Need of Advanced Therapy

    DIABETIC PATIENTS IN NEED OF ADVANCED THERAPY GPX-002 MAY ELIMINATE NEED FOR INSULIN IN DIABETIC PATIENTS Type 1 and Type 2 diabetes affect approximately 34 million people in the U.S1, or 10 percent of the U.S. population. May replace daily burden of blood glucose monitoring and insulin replacement

  30. Slide 30: GPX-002 Replenishes Levels of Insulin

    GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION Novel infusion process uses an endoscope and an AAV vector to deliver the Pdx1 and MafA genes to the pancreas. Transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinc

  31. Slide 31: Key Milestones Through Q1 2022 & Beyond

    KEY MILESTONES THROUGH Q1 2022 & BEYOND COMPLETED ANTICIPATED • Successful completion of technology transfer and scale-up • Initiate Acclaim-2 clinical trial in the first quarter of 2022 of REQORSA • Dose the first patient in each of the Acclaim clinical trials • Initiated site recruitment for both

  32. Slide 32: Some Targeted Therapy Company Valuations

    SOME TARGETED THERAPY COMPANY VALUATIONS DRUG COMPANY SYMBOL EXCHANGE INDICATION PHASE VALUATION CANDIDATE/TARGET Melanoma, Head and Neck, Iovance IOVA Nasdaq Cervical, NSCLC, Chronic Lifileucel, LN-145 Phase 3(1) $2.27 Billion Biotherapeutics Lymphocytic Leukemia NSCLC, Colorectal, Renal Mirati The

  33. Slide 33: Meet Our Team

    MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD CATHERINE VACZY, JD Chairman, President & Chief Executive Officer Executive VP, General Counsel & Chief Strategy Officer • 30+ years of expertise in corporate law, including corporate governance, in biotech industry • 20+ years of experience in seni

  34. Slide 34: Meet Our Team

    MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD HEMANT KUMAR, PHD Senior Vice President, Intellectual Property Chief Manufacturing & Technology Officer and Licensing • Recognized global expert in Chemistry, Manufacture • 20+ years of expertise in biotech IP law, business and Controls (CMC) Tec

  35. Slide 35: Scientific Advisory Board

    MEET OUR TEAM SCIENTIFIC ADVISORY BOARD PASI ANTERO JÄNNE JACK A. ROTH MD, PhD • Professor of Medicine, Harvard Medical School; MD, FACS, Chairman Director of Dana Farber Cancer Institute Lowe Center • Professor and Bud Johnson Distinguished Clinical for Thoracic Oncology; Scientific Director of the

  36. Slide 36: Clinical Advisory Board

    MEET OUR TEAM CLINICAL ADVISORY BOARD COL. GEORGE PEOPLES MICHAEL MORSE MD, FACS MD, MHS, FACP • Professor of Medicine, Division of Medical Oncology • Chief Executive Officer of Cancer Insight, LLC, a in the Department of Surgery at Duke University boutique cancer immunotherapy CRO • Research expert

  37. Slide 37: Board of Directors

    MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD Chairman of the Board BRENT LONGNECKER • 30+ years of expertise in corporate law, including Board Director corporate governance, in biotech industry • Former owner of securities broker dealer firm • Chief Executive Officer, Longnecker & Associates •

  38. Slide 38: Transformational 21st Century Gene Therapies

    21ST CENTURY GENE THERAPIES WE BELIEVE LARGE MARKETS AND UNMET NEED IN A FUTURE OF COMBINATION TRIALS WITH TOP TRANSFORMATIONAL SELLING DRUGS TWO FDA FAST TRACK DESIGNATIONS PATIENT CARE EXPLORING NEW INDICATIONS AND PARTNERSHIPS Nasdaq: GNPX 38

  39. Slide 39: Nasdaq: GNPX Contact

    NASDAQ: GNPX (877) 774 - GNPX | investors@genprex.com Nasdaq: GNPX

  40. Slide 40: Appendix

    APPENDIX Nasdaq: GNPX 40

  41. Slide 41: Two New Combination Clinical Trials

    TWO NEW COMBINATION CLINICAL TRIALS ONCOPREX® Nanoparticle Delivery System is the lipid nanoparticle delivery system used in REQORSA™. Nasdaq: GNPX 41

  42. Slide 42: Effects of Genetic Alterations in Suppressor Genes

    EFFECTS OF GENETIC ALTERATIONS IN SUPPRESSOR GENES The most common genetic alterations present in NSCLC are located in tumor-suppressor genes against which no targeted agents have been developed. ● Regulation of Malignant Tumor Growth ● Insensitivity to Growth-inhibitory Signals ● Evasions of Progra

  43. Slide 43: Why Systemic Gene Therapy?

    WHY SYSTEMIC GENE THERAPY? ● Lipid nanoparticles have been shown to encapsulate plasmid DNA, which allows the delivery of gene therapeutic agents intravenously to distant metastases ● Lipid nanoparticles with TUSC2 have up to a 33-fold affinity for cancer cells compared to healthy cells ● No need to

  44. Slide 44: Why TUSC2?

    WHY TUSC2? ● 80% of all lung cancer cells lack the TUSC2 tumor suppressor gene ● Loss or reduction of TUSC2 expression is associated with significantly worse overall survival ● Premalignant lesions express significantly lower levels of TUSC2 compared with normal bronchial epithelia Nasdaq: GNPX 44

  45. Slide 45: Viral vs. Non-Viral Vectors

    VIRAL VS. NON-VIRAL VECTORS The most common viral vectors are adenoviruses and retroviruses ● High level of transfection efficiency ● Generally stable ● Less specificity of target cells ● Can be immunogenic because capsid and viral proteins cause inflammation ● Reported cases of death and causing le

  46. Slide 46: Other Potential Cancer Indications

    OTHER POTENTIAL CANCER INDICATIONS The region of the TUSC2 tumor suppressor gene is associated with chromosome 3p. In addition to NSCLC, other potential indications include: ● Thyroid ● Renal ● Breast ● Head & Neck ● Mesothelioma ● Ovary Ivanova, A.V., Ivanov, S.V., Prudkin, L. et al. Mechanisms of

  47. Slide 47: REQORSA + Tagrisso Reduce Tumor Growth

    REQORSA + TAGRISSO REDUCE TUMOR GROWTH EFFECT OF TAGRISSO (OSIMERTINIB) + TUSC2 ON A549-LUC METASTASIS ON NSG MICE Osimertinib is the generic form of Tagrisso. Nasdaq: GNPX 47

  48. Slide 48: Effect of REQORSA + Carbo + Keytruda on Humanized A549 Lung Metastasis Model

    EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Effect of Carbo+Pembro+TUSC2 on A549 lung met on Hu-NSG 60000 **** % of change (wk2 vs wk5) 40000 tumor intensity 20000 *** 8000 *** 6000 4000 2000 0 2 t o 2 en SC SC br tm em TU TU ea +P o+ tr bo br o N em ar C +P bo ar C

  49. Slide 49: Effect of REQORSA + Carbo + Keytruda on Humanized A549 Lung Metastasis Model

    EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Effect of Carbo+Pembro+TUSC2 on A549 lung met on Hu-NSG 6×10 9 No treatment TUSC2 4×10 9 Carbo+Pembro Total Flux [p/s] Carbo+Pembro+TUSC2 2×10 9 2×10 8 1.5×10 8 1×10 8 *** 5×10 7 ** * 0 D14 D28 D35 *** p= 0.0003 vs No treat

Genprex — Investor Presentation (January 2022) on 6ix